TrialJournal of Crohn's & colitis2025

Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn's disease and ulcerative colitis: 2-year results from open-label extensions of two randomized controlled trials (LIBERTY).

Jean-Frederic Colombel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.